The Role of Dietary Approach in Irritable Bowel Syndrome

2019 ◽  
Vol 26 (19) ◽  
pp. 3512-3520 ◽  
Author(s):  
Piero Portincasa ◽  
Antony Lembo ◽  
Ornella de Bari ◽  
Domenica M. Di Palo ◽  
Anna Maggio ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Tract ◽  
Intestinal Microbiota ◽  
Intestinal Motility ◽  
Gastrointestinal Diseases ◽  
Functional Disorder ◽  
First Line ◽  
Dietary Education ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal tract and is one of the most frequent gastrointestinal diseases. In IBS multiple pathophysiological mechanisms including alterations in intestinal motility, permeability, nutrient absorption, and intestinal microbiota have been implicated. Foods are commonly reported by patients to be a trigger of symptoms and therefore are likely involved in the generation of symptoms in IBS. Among all possible therapeutic options, a first-line approach to IBS is dietary education and identification of foods potentially responsible for the onset or worsening of symptoms. Dietary approaches include reduction of gas-producing foods (i.e. fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs)), lactose and gluten. Further studies are required to link the ultimate role of diets in different IBS subtypes.

The role of intestinal microbiota in the development of urolithiasis in patients with an irritable bowel syndrome

2020 ◽  
Vol 0 (3) ◽  
pp. 29-36
Author(s):  
I. A. Derkach ◽  
A. E. Dorofeyev ◽  
M. M. Rudenko ◽  
G. A. Dorofeyeva ◽  
Yu. Z. Dynia
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Microbiota ◽  
Irritable Bowel

scholarly journals The role of intestinal microbiota in irritable bowel syndrome

2018 ◽  
Vol 72 ◽  
pp. 215-226
Author(s):  
Tomasz Dworzański ◽  
Rafał Fornal ◽  
Łukasz Koźba ◽  
Krzysztof Celiński ◽  
Ewa Dworzańska
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Microbiota ◽  
Human Body ◽  
Intestinal Flora ◽  
Faecal Flora ◽  
Vast Number ◽  
Beneficial Effects ◽  
Irritable Bowel ◽  
Micro Organisms

In recent years, impressive advances in the knowledge about a vast number of microbes living in the human body and interactions between the microbiota and the human body have been observed. All micro-organisms that live in the human body consist of around 10 ^ 14 cells. The number of microbial cells colonizing the human body is ten times higher than the number of its own cells and the weight of all micro-organisms is about 2-2.5 kg. The number of bacterial genes is 50-100 times greater than the number of genes in the human body. Nowadays, the human microbiota is often regarded as a “newly discovered organ” or even as a “supergenome”. The results of many studies have revealed that disruption of the bowel microecosystem may affect the development of irritable bowel syndrome (IBS) symptoms. Therefore, manipulation of the gut microflora was hoped to be a new tool in the treatment of this disease. Various methods (probiotics, prebiotics, antibiotic therapy, transplantation of faecal flora) have been used to modify the intestinal microbiota by supporting the expansion of bacteria considered beneficial and reducing the number of those regarded as harmful, thus alleviating the IBS symptoms. There is much evidence in the literature to suggest that the intestinal microbiota and the gut-intestinal axis are important factors in the pathogenesis of IBS. Moreover, the literature findings have demonstrated beneficial effects of modifying the intestinal flora composition in alleviating IBS symptoms. Although the pathophysiology of IBS and the role of the intestinal microflora and gut-intestinal axis in it are well known, many issues are still to be elucidated. Further research into the bacteria identified in stool and colon mucosa of healthy individuals should provide more information on restoration of intestinal homeostasis in IBS patients.

scholarly journals How to improve effectiveness of treatment of patients with irritable bowel syndrome?

2021 ◽  
pp. 134-140
Author(s):  
E. V. Golovanova
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Microbiota ◽  
Symptom Severity ◽  
Clinical Symptoms ◽  
Functional Gastrointestinal Disorders ◽  
Gastrointestinal Diseases ◽  
Controlled Study ◽  
Bacterial Strains ◽  
Double Blind ◽  
Irritable Bowel

This article discusses ways to improve the effectiveness of treatment of irritable bowel syndrome (IBS), one of the most common functional gastrointestinal disorders (FGID). The significance of this issue is caused by high frequency of pathology detection among the young employable population and the difficulties in choosing an effective treatment that relieves not only the symptom severity, but also the frequency of relapses. Inadequate therapy reduces patients’ compliance with treatment and significantly worsens their quality of life. The choice of a drug that fails to provide a positive effect on all factors that form the pain syndrome is the most common reason for ineffective treatment. In addition, the measures aimed at managing such pathogenic factors as intestinal microbiota dysbiosis are often not taken. Meanwhile, numerous studies have shown that the intestinal microbiota imbalance is accompanied by increased intestinal permeability, which leads to the penetration of aggressive agents through extended intercellular spaces. This is accompanied by the occurrence of subclinical inflammation in the submucosal layer, which results in impaired motor function and increased visceral sensitivity. Thus, the intestinal microflora imbalance is one of the most important factors that form clinical symptoms of IBS. The article substantiates the advantages of using trimebutin, a gastrointestinal tract motility regulator, in functional gastrointestinal diseases from the standpoint of evidence-based medicine. The modern scientific knowledge on the  effectiveness of  microbiota  adjustment in  alleviating IBS symptoms is presented. In  particular, the  double-blind, placebo-controlled study has shown the efficacy of a multi-strain probiotic complex in relieving clinical symptom severity of IBS. The optimal treatment regimen for a patient with IBS should include a drug regulating the gastrointestinal motility and reducing visceral hypersensitivity and a probiotic complex containing bacterial strains that have proved their efficacy in this group of patients. 

scholarly journals The relevance of probiotics in therapy

2021 ◽  
Vol 11 (8) ◽  
pp. 80-85
Author(s):  
Konrad Grzeszczak ◽  
Aleksandra Strońska ◽  
Karolina Rogulska
Keyword(s):  
Helicobacter Pylori ◽  
Irritable Bowel Syndrome ◽  
Tract Infection ◽  
Respiratory Tract ◽  
Respiratory Tract Infection ◽  
Intestinal Microbiota ◽  
Gastrointestinal Diseases ◽  
Irritable Bowel ◽  
The Impact ◽  
Positive Effect

Probiotics are live microorganisms that have a positive effect on human health, in particular on the intestinal microbiota. It turned out that they not only perform an important role in the intestinal microbiota, but also affect the functioning of the immune system, reduce the incidence of allergies or significantly reduce the risk of certain types of cancer. Thanks to the proven benefits of probiotics, scientists are now looking into their use in the treatment of many diseases. The examples are Helicobacter pylori infection, Irritable Bowel Syndrome and Respiratory Tract Infection, where the significant benefits of probiotics have been proved. Until recently it was thought that they were only useful in gastrointestinal diseases, but the use of probiotics in Respiratory Tract Infection shows that probiotics can also be used to treat other diseases. Further research into the impact of probiotics on therapy is highly desirable in order to match the effects of specific strains to specific diseases.

scholarly journals Giardiasis and post-infectious bowel syndrome

2021 ◽  
pp. 178-187
Author(s):  
A. A. Belova ◽  
M. D. Shestakova ◽  
A. I. Khavkin
Keyword(s):  
Immune Response ◽  
Irritable Bowel Syndrome ◽  
Gastrointestinal Tract ◽  
Species Composition ◽  
Intestinal Microbiota ◽  
Mucosal Barrier ◽  
Irritable Bowel ◽  
The Moment ◽  
High Level ◽  
Post Infectious

Post-infectious irritable bowel syndrome — one of the most frequent conditions diagnosed in pediatric gastroenterological practice. According to numerous research parisitosis contributes to the chronology of gastrointestinal tract pathology. it is known that the infection Lamblia intestinalis can increase the risk of developing post-infectious IBS, changing species composition and diversity of the intestinal microbiota, modulating metabolism of the host, the nature of the immune response and adversely affecting the mucosal barrier and the motility of the digestive tract. Importantly, the prevalence of giardiasis in patients with symptoms of IBS and dyspepsia at the moment, it remains at a high level. Further research into the pathogenesis of Lamblia intestinalis infection in patients with IBS will be of great importance in medicine.

scholarly journals Experimental Models of Irritable Bowel Syndrome and the Role of the Enteric Neurotransmission

2017 ◽  
Author(s):  
Maria Giuliana Vannucchi ◽  
Stefano Evangelista
Keyword(s):  
Irritable Bowel Syndrome ◽  
Maternal Separation ◽  
Visceral Pain ◽  
Gastrointestinal Diseases ◽  
Experimental Models ◽  
Main Role ◽  
Cellular Mechanisms ◽  
Neonatal Maternal Separation ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal diseases in humans. It is characterized by visceral pain and/or discomfort, hypersensitivity and abnormal motor responses along with change in gut habits. Although the etio-pathogenesis of IBS is only partially understood, a main role has been attributed to psychosocial stress of different origin. Animals models such as neonatal maternal separation, water avoidance stress and wrap restraint stress have been developed as psychosocial stressors in the attempt to reproduce the IBS symptomatology and identify the cellular mechanisms responsible for the disease. The study of these models has led to the production of drugs potentially useful for IBS treatment. This review intends to give an overview on the results obtained with the animal models; to emphasize the role of the enteric nervous system in IBS appearance and evolution and as a possible target of drug therapies.

scholarly journals Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome

Pathogens ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1545
Author(s):  
Tomasz Wollny ◽  
Tamara Daniluk ◽  
Ewelina Piktel ◽  
Urszula Wnorowska ◽  
Anna Bukłaha ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Current Knowledge ◽  
World Population ◽  
Functional Disorder ◽  
The Central Nervous System ◽  
Health And Disease ◽  
Irritable Bowel ◽  
Functional Responsiveness

Irritable bowel syndrome (IBS) is a common, chronic, functional disorder with a large impact on world population. Its pathophysiology is not completely revealed; however, it is certain that dysregulation of the bidirectional communications between the central nervous system (CNS) and the gut leads to motility disturbances, visceral hypersensitivity, and altered CNS processing characterized by differences in brain structure, connectivity and functional responsiveness. Emerging evidence suggests that gut microbiota exerts a marked influence on the host during health and disease. Gut microbiome disturbances can be also important for development of IBS symptoms and its modulation efficiently contributes to the therapy. In this work, we review the current knowledge about the IBS therapy, the role of gut microbiota in pathogenesis of IBS, and we discuss that its targeting may have significant impact on the effectiveness of IBS therapy.

The putative role of the intestinal microbiota in the irritable bowel syndrome

2009 ◽  
Vol 41 (12) ◽  
pp. 850-853 ◽  
Author(s):  
S.M. Collins ◽  
E. Denou ◽  
E.F. Verdu ◽  
P. Bercik
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Microbiota ◽  
Putative Role ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document